IRRAS publishes Interim Report for the period January to June 2019
US sales started“During the second quarter, we reached a significant milestone by recording our first IRRAflow revenue in the United States (US). The US is the world´s largest market for neurosurgical procedures, and with the ongoing CE Mark recertification process, we have focused much of our team´s resources toward supporting a successful early market introduction in the US.” Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS Second quarter, April - June 2019 · Net revenue totaled SEK 1.1 million (0.1) · Operating loss (EBIT) amounted to SEK -40.7 million (-32.1)